Overall, we observed that expression of MAPK, NFκB and p21 pathway components were noted in most cTCL tumors which was expected based on the frequency of highly mutated (>7 mutations) genes for MET (92%), KDR (92%), STK11 (67%) and BRAF (50%) (Figure 2D and Figure 3C). The gene discussed is STK11; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.